Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Shares Shorted: Short Interest Down 69.1% in September
by Danessa Lincoln · The Markets DailyCreative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 84,256 shares, a decline of 69.1% from the August 31st total of 272,812 shares. Based on an average daily trading volume, of 172,085 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.3% of the shares of the stock are sold short.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on CELZ shares. Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Finally, Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Creative Medical Technology has a consensus rating of “Hold”.
Get Our Latest Research Report on CELZ
Creative Medical Technology Stock Performance
Shares of CELZ traded up $0.06 during midday trading on Friday, hitting $1.03. 318,235 shares of the company traded hands, compared to its average volume of 1,251,462. The stock has a market cap of $6.79 million, a price-to-earnings ratio of -0.50 and a beta of 2.04. The firm has a 50 day moving average of $1.01 and a 200-day moving average of $1.62. Creative Medical Technology has a 52 week low of $0.62 and a 52 week high of $6.25.
Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Sell-side analysts predict that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cell-based therapies. The company’s research programs are aimed at conditions involving inflammation, autoimmune dysfunction, tissue damage and sexual health.
Its pipeline has included ImmCelz, an immunomodulatory cell-therapy platform, as well as CaverStem for erectile dysfunction, FemCelz for female sexual health, KneeCelz for knee-related conditions and StemSpine for spinal disorders.